Taro Pharmaceuticals U.S.A., Inc.

Taro Pharmaceuticals U.S.A., Inc.

Company History:

Established in Israel in 1950, Taro Pharmaceutical Industries Ltd., Taro’s parent company, is a research-based, international specialty pharmaceutical company that develops, manufactures, and markets quality prescription and over-the-counter pharmaceutical products. Taro focuses on Generics, Brands, OTC-Private Label, and API synthesis. Taro currently markets over 300 finished goods products, and the Company produces API for over 100 SKUs. In calendar year 2014, based on industry data, Taro again exceeded sales of over $1 billion dollars in the US market. Industry data also ranked Taro as the #1 Generic Dermatology Supplier for the third year in a row.

Business Areas:

Generics:

Taro’s generics are a key foundation of its US business. Taro’s generic products consist of over 250 SKUs, many of which are vertically integrated with Taro’s unique API in-house source. Taro has an award winning sales team that has been recognized by numerous major customers’ awards. Taro is an industry leader in both generic and brand manufacturing and distribution, with service levels above 98%. Taro utilizes several unique processing and supply chain procedures that enable the Company to provide the excellent service rates.

Brands:

The Taro brand business team is focused on 7500 dermatologists. The specialty detail force has approximately 70 field representatives calling on physicians. Taro’s management team has a deep rooted network with the top key opinion leaders in Dermatology. Taro continues to focus its detailing efforts around Topicort® (desoximetasone) Topical Spray, 0.25%. This product has been a strong contributor to the existing Topicort® line. The brand team at Taro has numerous product development projects as well as external partnerships in the Dermatology arena.

OTC-Private Label

Taro’s OTC-Private Label team is focused on dermatology and allergy products in both Taro and store brand labels. It is a dedicated and seasoned team that utilizes Taro sales personnel as well as a broker network to promote products. The product family consists of topical foot care, first aid, and feminine health categories along with cough/cold/allergy tablets, oral solutions, and powder for oral solution. On many of these items Taro is the market leader. Taro is anticipating significant growth for this sector stemming from the projected trend of products switching from prescription to OTC as well as our recent rebranding efforts around FeverAll® suppositories.

Active Pharmaceutical Ingredient (API):

Taro originally started API manufacturing in the 1960s. This enables Taro to manufacture both the API and finished dosage form for many key medications, allowing the Company to tightly control quality and consistency of supply. The vertical integration on API allows Taro to be cost competitive in the generic drug business.

Manufacturing Capabilities:

Taro has state of the art manufacturing facilities in Israel and Canada. The manufacturing site in Israel includes manufacturing of numerous dosage forms to include extended release and NTI products. The facility in Canada is a modern, high efficiency manufacturing site specializing in semi-solid and oral and topical solution dosage forms. The facilities in Israel and Canada are also home to Taro’s international sales and marketing teams. Both manufacturing sites have R&D capabilities as well as advanced product development capabilities.

Industry Performance/Financials:

Taro is very proud of its product market share position. Taro products rank first or second in market share for over 65% of its portfolio. Taro’s US customer mix is well diversified among retail chains, drug wholesalers and managed care providers, delivering a well-balanced market presence. Taro has made significant financial and operational improvements combined with steady growth over the last five years. The Company has seen strong improvements in key metrics such as net sales, gross profit, net income, and debt reduction. Additionally, Taro has a significant cash position to provide a platform for growth, along with a strong backing of Sun Pharmaceutical Industries Ltd., a major shareholder of Taro with an international presence in the generic pharmaceutical industry. Taro is publicly traded on the New York Stock Exchange, symbol TARO.

Taro Pharmaceuticals U.S.A., Inc.

Chief Executive Officer
Kal Sundaram

Chief Commercial Officer
Generic Rx and OTC
Michael Perfetto

Executive Director, Rx Brand
Ralph Bohrer

Address: 3 Skyline Drive
Hawthorne, NY 10532

Phone: 1-800-544-1449
Website: www.taro.com